BioCorRx Announces Collaboration with the One Day at a Time Program in Philadelphia
ANAHEIM, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a pilot for the BioCorRx® Recovery Program in collaboration with the One Day at a Time Program (ODAAT), a program funded by the city of Philadelphia and state of Pennsylvania. This will be a paid demonstration pilot in which the BioCorRx Recovery Program will be used to treat several individuals suffering from opioid and alcohol use disorders. The ODAAT program assists over 56,000 residents of Philadelphia.
ODAAT is dedicated to serving low-income and homeless men and women and their families in the Philadelphia area who are afflicted by addiction and HIV/AIDS. ODAAT is also building stronger communities through their anti-violence and recovery initiatives. ODAAT’s focus is on providing peer support and promoting healthy, positive lifestyles. ODAAT accomplishes its mission through a holistic array of services, including addiction recovery counseling, linkage to health and social services, transitional housing, and community outreach.
The BioCorRx® Recovery Program includes the use of a naltrexone implant produced per patient prescription, combined with the Company’s proprietary cognitive behavioral therapy (CBT) program and overlapping 12 months of peer support. These specifically formulated, biodegradable pellets are typically inserted beneath the skin in the lower abdominal area. Naltrexone is a non-addictive opioid antagonist used for the treatment of alcohol and opioid use disorders. It can reduce or eliminate cravings for alcohol and opioids, as well as block the dangerous effects of opioid use such as overdose, as commonly seen with heroin. The implant provides a window of opportunity for one to get through the behavioral therapy component and well established into the peer support portion of the program.
Mel Wells, President of One Day at a Time Program, commented, “As recovery providers, we cannot continue to sit by and watch our loved ones and family members die. Thanks to BioCorRx's support and expertise, together we will be able to make a resounding impact in saving lives against addiction.”
Pennsylvania State Senator Sharif Street, stated, “Given the tremendous challenges placed on the community by the opioid epidemic, I am excited that One Day at A Time continues to be a leader and innovator in the recovery space. One Day at a Time has a track record of helping people overcome addiction and I am hopeful that they are equally successful in the implementation of this new, innovative and potentially lifesaving process for addressing opioid addiction and recovery.”
Brady Granier, President, CEO and Director of BioCorRx, stated, “We are pleased to have such great support for our recovery program in Pennsylvania. The BioCorRx® Recovery Program continues to gain momentum as independent treatment providers across the country report successful results using our program to treat their patients.”
Tom Welch, VP Operations of BioCorRx commented, “We are thrilled to be working with Mel, ODAAT and the great people of Pennsylvania. We look forward to making a significant and positive impact in this insidious epidemic.”
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. investors@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 email@example.com
Released January 24, 2018